Elacestrant not checked
Stemline Therapeutics, Inc. · RAD1901 · ER-306323
FollowEvery change as it happens, and a Monday email
Trials
16 active
20 in total · 15 in the EU
What this is
- How it works
- Blocks oestrogen from acting on cells. Used against breast cancer that oestrogen feeds.Estrogen Receptor Antagonist FDA class
- How it’s given
- “Starting dose 400 mg elacestrant dihydrochloride administered orally once daily for an estimated 6 months of treatment.”In the company’s words, NCT05596409 on ClinicalTrials.gov
- Tested for
- Breast Cancer (3 trials), Metastatic Breast Cancer (2 trials), Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms and 3 more
- Main trialPhase 3
- “The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.”In the company’s words, NCT06492616 on ClinicalTrials.gov
- Other names
- RAD1901 · ORSERDU · ER-306323
Other drugs for Breast Cancer
- D-0502InventisBio Co., Ltd · Phase 3
- YL202MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- SPH4336Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- NiraparibGSK · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
Coming up6
- NovPhase 2 trial completes · ClinicalTrials.gov
- 27 DecPhase 1/2 trial completes · ClinicalTrials.gov
- DecPhase 1/2 trial completes · ClinicalTrials.gov
- 24 Oct 2027Phase 1 trial completes · ClinicalTrials.gov
- Oct 2028Phase 2 trial completes · ClinicalTrials.gov
- Aug 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials20
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Aug 2029 | A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | |
| Phase 2Active, not recruiting | Nov 2026 | ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study | |
| Phase 2Recruiting | Oct 2028 | A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer | |
| Phase 1/2Active, not recruiting | 27 Dec 2026 | Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer | |
| Phase 1/2Recruiting | Dec 2026 | Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | |
| Phase 1Recruiting | 24 Oct 2027 | A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer | |
| Phase 3Completed | 24 Aug 2021 | Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | |
| Phase 1Completed | 30 Aug 2018 | Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer | |
| Phase 1Completed | Sep 2019 | A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer | |
| Phase 1Completed | 11 Nov 2024 | A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function | |
| Phase 3Authorised | not given | EORTC 2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA) | |
| Phase 2Authorised | not given | Phase II, multicenter, randomized, open-label study of premenopausal women with luminal breast cancer investigating the effect of oral SERD elacestrant with/without triptorelin in the ER functional pathway and Ki67 proliferation. Preoperative trial – PremiÈRe | |
| Phase 2Authorised | not given | Phase II study evaluating the addition of elacestrant, an oral selective estrogen receptor degrader (SERD), to standard-of-care olaparib in patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with gBRCA1/2 mutations – ELEMENT | |
| Phase 2Authorised | not given | ABCSG 63 / ERIKA: Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer: An open-label, two-arm, randomized, phase II study of elacestrant plus ribociclib vs. AI (plus GnRH agonist in pre-/perimenopausal women and men) plus ribociclib as neoadjuvant therapy for endocrine-responsive HER2-negative early breast cancer | |
| Phase 3Authorised | not given | A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors - The ADELA study- | |
| Phase 2Authorised | not given | Elacestrant and exemestane for patients with pretreated HR+/HER2- metastatic breast cancer and [18F]-FES-avid lesions (COMBINE): a proof-of-concept phase 2 clinical trial | |
| Phase 2Authorised | not given | POP-ELA: A short-term preoperative, window-of-opportunity study, evaluating activity and safety of Elacestrant monotherapy as compared to Elacestrant + ovarian function suppression (LHRH agonist) in premenopausal patients with stage I-II ER+/HER2- breast cancer | |
| Phase 2Authorised | not given | Hormonal Receptor (HR)-positive HER2 negative breast cancer patients treated with preoperative ELacestrant and PULSAR adaptive radiotherapy: a phase II study | |
| Phase 3Authorised | not given | Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/or clinically high-risk ER+/HER2- early breast cancer (ADAPTela) | |
| Phase 2Authorised | not given | A multicenter, multicohort, phase 2 platform trial to personalize second-line treatment intensity and targeting in HR-positive, HER2-negative metastatic breast cancer through an integrated liquid biopsy algorithm. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026